-
Disruptive behaviors are a poor prognostic sign in patients with Alzheimer's disease.
-
Wyeth Pharmaceuticals has received approval to market desvenlafaxine for the treatment of depression. The drug is the major active metabolite of venlafaxine (Effexor ). Wyeth has formulated the drug in a once-daily extended-release tablet. It will be marketed under the trade name Pristiq.
-
Lower serum testosterone in men aged 60 and over was associated with increased fracture risk (especially hip and nonvertebral), even after adjusting for other major risk factors for fracture.
-
Neither training in working techniques nor use of lifting equipment appears to prevent back pain or back-related disability.
-
This single center prospective observational study finds that the utility of a routine daily chest x-ray (CXR) for an ICU patient is quite limited. A change in practice to ordering CXR only when clinically indicated did not adversely impact patient outcome but reduced CXR volume and overall costs.
-
The greatest challenge for any potentially mortal disorder is to prove that therapeutic interventions reduce not only disease-specific mortality, but also all-cause mortality.
-
-
-
Most cases of thrombocytopenia seen are expected. Patients are known to have hematological disease or are receiving chemotherapy. At times, however, the physician is confronted with an unexpected laboratory finding in an asymptomatic patient, or with a patient who is bleeding. The challenge, as usual, is to determine the need for acute treatment and the appropriate disposition.
-
Stop smoking drug Chantix rates stronger warning from FDA; Type 2 diabetes surgery on the way?; Vytorin study inconclusive; Influenza A virus found resistant to Tamiflu; FDA actions.
